Review
Medicine, General & Internal
Kaleen N. Hayes, Elizabeth M. Winter, Suzanne M. Cadarette, Andrea M. Burden
Summary: Bisphosphonates are the primary treatment for osteoporosis, and a drug holiday of two to three years is recommended for most patients after long-term use to reduce the risk of adverse events. Duration of bisphosphonate effects during the drug holiday and individual patient factors should be considered when determining the appropriate time to stop therapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Gregory A. A. Kline, Suzanne N. N. Morin, Lisa M. M. Lix, William D. D. Leslie
Summary: Based on the FLEX study in 2006, a 5-year course of bisphosphonate therapy was found to be sufficient for most women. However, despite the increased risk of atypical femoral fractures associated with long-term use, up to one-third of patients continued to receive bisphosphonate therapy for over 10 years after 2010.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Gregory A. Kline, Suzanne N. Morin, Lisa M. Lix, William D. Leslie
Summary: This study examined medication adherence in women with osteoporosis before and after a fracture. The results show that many women experience a decline in medication adherence after a fracture, which is paradoxical to expectations. Fracture on therapy represents an important opportunity for clinicians to emphasize treatment adherence.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Nicholas R. Fuggle, Beth Curtis, Michael Clynes, Jean Zhang, Kate Ward, Muhammad Kassim Javaid, Nicholas C. Harvey, Elaine Dennison, Cyrus Cooper
Summary: Despite significant progress in understanding osteoporosis over the past three decades, there is still a treatment gap where many high-risk individuals go untreated. This review highlights the patient, physician, and policy-related factors contributing to this gap, and focuses on discussing the efficacy and adverse effects of bisphosphonates in osteoporosis treatment, as well as strategies to improve prevention pathways for the disorder.
Review
Medicine, General & Internal
SeokJoon Hwang, Minsu Seo, Dongin Lim, Min Suk Choi, Jin-Woo Park, Kiyeun Nam
Summary: This literature review investigated the characteristics and management of bisphosphonate-associated bilateral atypical femoral fractures (AFFs). A comprehensive analysis of 43 patients with bilateral AFFs revealed that 67% had prodromal symptoms, 49% occurred simultaneously, and 51% occurred sequentially. X-ray was used for initial diagnosis, with 53% having complete fractures. Surgical treatment was performed for all patients, except for those with incomplete fractures who received either surgical or medical treatments. Teriparatide was the most commonly used medication after bisphosphonate discontinuation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Nutrition & Dietetics
Antonino Catalano, Federica Bellone, Domenico Santoro, Peter Schwarz, Agostino Gaudio, Giorgio Basile, Maria Carmela Sottile, Sabrina Atena Stoian, Francesco Corica, Nunziata Morabito
Summary: Vitamin D supplementation can increase bone density in postmenopausal women, especially after discontinuation of alendronate. Changes in 25-hydroxyvitamin D levels are associated with changes in bone mineral density.
Article
Health Care Sciences & Services
Sara Jane Cromer, Kristin M. D'Silva, Elaine W. Yu, Joan Landon, Rishi J. Desai, Seoyoung C. Kim
Summary: The study found that the use of denosumab has surpassed all other bone-directed therapies over the past decade, especially since its approval in 2010. The use of denosumab also showed increasing trends among patients with osteoporosis, malignancies, and recent fractures. However, it is noteworthy that the proportion of using any bone-directed therapy after fractures is low and has declined over time.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Ian R. Reid, Anne M. Horne, Borislav Mihov, Sonja Bastin, Gregory D. Gamble
Summary: Bisphosphonates are commonly used for osteoporosis prevention and treatment, while NSAIDs are widely used by older adults at high fracture risk. A study reanalyzed data from a clinical trial of zoledronate and found that NSAID use did not affect the bone density or fracture risk reduction effects of zoledronate. The study concluded that NSAIDs do not interfere with the efficacy of potent bisphosphonates in terms of bone density or fracture.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Michael Morkos, Paul Mahrous, Alessandra Casagrande, Muriel Tania Go, Hasan Husni, Mirette Hanna, Mishita Goel, Sara Bedrose, Dingfeng Li, Sanford Baim
Summary: This study aimed to investigate physicians' preferences and sequential treatment patterns of osteoporosis therapy. The study found that alendronate was the most common initial treatment, and denosumab was the most common second course of treatment prescribed.
ENDOCRINE PRACTICE
(2022)
Article
Orthopedics
Di-chen Zhao, Xiao-yun Lin, Jing Hu, Bing-na Zhou, Qian Zhang, Ou Wang, Yan Jiang, Wei-bo Xia, Xiao-ping Xing, Mei Li
Summary: Men with osteoporosis have significantly impaired health-related quality of life, and the severity of osteoporosis is negatively correlated with quality of life. Fragility fracture is an important factor contributing to decreased quality of life. Treatment with bisphosphonates can improve the health-related quality of life in men with osteopenia/osteoporosis.
BMC MUSCULOSKELETAL DISORDERS
(2023)
Article
Chemistry, Physical
Fanouria-Eirini G. Alatzoglou, Maria Vassaki, Kalliopi Nirgianaki, Eleftherios Tripodianos, Petri Turhanen, Konstantinos D. Demadis, Konstantinos E. Papathanasiou
Summary: Bisphosphonate drugs are effective for treating bone diseases, but they have drawbacks such as rapid excretion and limited bioavailability. This study presents novel silica-based hydrogels loaded with the osteoporosis drug etidronate for controlled drug release. Various methods were evaluated to control the release rate and concentration, including gel density, metal cations, and surface functionalization. This research contributes to the development of programmable drug-loaded gels for controlled release of osteoporosis drugs.
Article
Endocrinology & Metabolism
Gregory A. Kline, Suzanne N. Morin, Lisa M. Lix, William D. Leslie
Summary: Bone mineral density (BMD) loss shows greater variability at shorter testing intervals, but this variability diminishes over longer intervals. Using reports of rapid BMD loss as an indication for antifracture medication initiation may not be accurate.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Geriatrics & Gerontology
Nicholas Fuggle, Nasser Al-Daghri, Olivier Bock, Jaime Branco, Olivier Bruyere, Enrique Casado, Etienne Cavalier, Bernard Cortet, Maarten de Wit, Andrea Giusti, Philippe Halbout, Nicholas C. Harvey, Mickael Hiligsmann, Jean-Marc Kaufman, Andreas Kurth, Stefania Maggi, Radmila Matijevic, Salvatore Minisola, Santiago Palacios, Regis Pierre Radermecker, Friederike Thomasius, Sansin Tuzun, Nicola Veronese, John A. Kanis, Jean-Yves Reginster, Rene Rizzoli, Cyrus Cooper
Summary: Oral bisphosphonates are important in the treatment of osteoporosis, but poor adherence is a problem. New formulations aim to improve tolerance and adherence, potentially leading to better fracture outcomes.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Endocrinology & Metabolism
Katherine A. P. Ralston, Jonathan Phillips, Amrey Krause, Barbara Hauser, Stuart H. Ralston
Summary: Presenting the benefits of osteoporosis treatment as an absolute risk reduction (ARR) rather than a relative risk reduction (RRR) leads to decreased acceptance of treatment, particularly among patients with lower fracture risk.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Nerea Ugartondo, Nuria Martinez-Gil, Monica Esteve, Natalia Garcia-Giralt, Neus Roca-Ayats, Diana Ovejero, Xavier Nogues, Adolfo Diez-Perez, Raquel Rabionet, Daniel Grinberg, Susanna Balcells
Summary: Osteoporosis, a common metabolic bone disorder, is often treated with nitrogen-containing bisphosphonates. Prolonged use of bisphosphonates may lead to rare atypical femoral fractures, possibly due to rare mutations in the CYP1A1 gene.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
M. Amine Amiche, Linda E. Levesque, Tara Gomes, Jonathan D. Adachi, Suzanne M. Cadarette
JOURNAL OF BONE AND MINERAL RESEARCH
(2018)
Article
Pharmacology & Pharmacy
Marina Simeonova, Frank de Vries, Sander Pouwels, Johanna H. M. Driessen, Hubert G. M. Leufkens, Suzanne M. Cadarette, Andrea M. Burden
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2018)
Article
Clinical Neurology
Brian Chun-Fai Chan, Suzanne M. Cadarette, Walter P. Wodchis, Murray D. Krahn, Nicole Mittmann
JOURNAL OF SPINAL CORD MEDICINE
(2019)
Article
Medicine, General & Internal
Joann K. Ban, Mina Tadrous, Amy X. Lu, Erin A. Cicinelli, Suzanne M. Cadarette
Article
Endocrinology & Metabolism
M. Amine Amiche, Shahab Abtahi, Johanna H. M. Driessen, Peter Vestergaard, Frank de Vries, Suzanne M. Cadarette, Andrea M. Burden
ARCHIVES OF OSTEOPOROSIS
(2018)
Article
Endocrinology & Metabolism
Yina Xu, Tara Gomes, Muhammad M. Mamdani, David N. Juurlink, Suzanne M. Cadarette, Mina Tadrous
CANADIAN JOURNAL OF DIABETES
(2019)
Article
Substance Abuse
Qi Guan, Beth A. Sproule, Simone N. Vigod, Suzanne M. Cadarette, Simon Greaves, Diana Martins, Tara Gomes
Article
Endocrinology & Metabolism
R. Sujic, D. E. Beaton, M. Mamdani, S. M. Cadarette, J. Luo, S. Jaglal, J. E. M. Sale, R. Jain, E. Bogoch
OSTEOPOROSIS INTERNATIONAL
(2019)
Article
Endocrinology & Metabolism
K. N. Hayes, J. K. Ban, G. Athanasiadis, A. M. Burden, S. M. Cadarette
OSTEOPOROSIS INTERNATIONAL
(2019)
Article
Endocrinology & Metabolism
J. K. Ban, B. B. Hao, L. McCarthy, S. J. T. Guilcher, S. M. Cadarette
OSTEOPOROSIS INTERNATIONAL
(2019)
Article
Endocrinology & Metabolism
Giovanni Adami, Ayesha Jaleel, Jeffrey R. Curtis, Elizabeth Delzell, Rui Chen, Huifeng Yun, Shanette Daigle, Tarun Arora, Maria I. Danila, Nicole C. Wright, Suzanne M. Cadarette, Amy Mudano, Jeffrey Foster, Kenneth G. Saag
JOURNAL OF BONE AND MINERAL RESEARCH
(2020)
Article
Multidisciplinary Sciences
Catherine Beauregard-Paultre, Claire Nour Abou Chakra, Allison McGeer, Annie-Claude Labbe, Andrew E. Simor, Wayne Gold, Matthew P. Muller, Jeff Powis, Kevin Katz, Suzanne M. Cadarette, Jacques Pepin, Louis Valiquette
Article
Medicine, General & Internal
Mitchell H. Gail, Douglas G. Altman, Suzanne M. Cadarette, Gary Collins, Stephen J. W. Evans, Peggy Sekula, Elizabeth Williamson, Mark Woodward
Review
Medicine, General & Internal
Kaleen N. Hayes, Elizabeth M. Winter, Suzanne M. Cadarette, Andrea M. Burden
Summary: Bisphosphonates are the primary treatment for osteoporosis, and a drug holiday of two to three years is recommended for most patients after long-term use to reduce the risk of adverse events. Duration of bisphosphonate effects during the drug holiday and individual patient factors should be considered when determining the appropriate time to stop therapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Natalia Konstantelos, Andrea M. Burden, Angela M. Cheung, Sandra Kim, Paul Grootendorst, Suzanne M. Cadarette
Summary: This study aimed to compare fracture rates estimated using different definitions and found that coding decisions have a significant impact on fracture outcome definitions. The study highlights the importance and impact of coding decisions on fracture outcome identification and emphasizes the need for further research to inform best practice in fracture outcome identification.